ArticleDiscover oncology2026
Common crosstalk genes and molecular mechanisms in Helicobacter pylori infection and colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Epidemiological evidence indicates that HP-I increases the risk of CRC, yet the underlying pathological mechanisms remain unclear. This study aimed to identify DEGs associated with HP-I and CRC by analyzing public RNA sequencing data and to investigate potential molecular pathways. Gene expression profiles of HP-I and CRC were obtained from the GEO and TCGA databases. Shared DEGs were identified, followed by functional annotation, PPI network construction, hub gene identification, and validation of hub gene expression and diagnostic and prognostic value in CRC. Immune infiltration analysis, TFs prediction for hub genes, and potential small-molecule compound screening were also performed. A total of 112 shared DEGs were identified, including 74 up-regulated genes and 38 down-regulated genes. Enrichment analysis indicated that these DEGs were predominantly involved in immune and inflammation-related pathways. Eight hub genes (AGT, CCL20, CXCL1, CXCL2, CXCL5, CXCL9, CXCL10, and MMP9) were identified as central players contributing to the development of comorbid HP-I and CRC. Notably, these genes demonstrated good diagnostic performance in CRC, with AUC values ranging from 0.682 to 0.933. CXCL1 and CXCL9 were identified as prognostic markers for CRC. Immune infiltration analysis revealed a significant dysregulation of CD4⁺ T cell subsets in the context of HP-I and CRC. Finally, DY-131 was identified as a potential therapeutic candidate through the CMap database. This study reveals the potential common molecular mechanisms between HP-I and CRC, identifies shared hub genes, and highlights candidate therapeutic compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.